

IREDELL HEALTH SYSTEM

Medication Management in Infusion Care Services (ICS)	
Approved by: Randi Raynor, PharmD, MBA, BCPS	Last Revised Date: 10/2023
Pharmacy & Therapeutics Committee	Date: 12/2023

Policy

To ensure all medications given in ICS are safe, efficacious and cost-effective.

All medications, except chemotherapy, must be reviewed by the P&T Committee before administering in the ICS. Evaluations of additions and deletions to the list of restricted medications will be carried out as needed by the P&T Committee.

The following medications will be restricted from being administered in ICS.

Restricted Medications:

- Abatacept (Orencia)
- Adalimumab (Humira)
- Belimumab (Benlysta)
- Denosumab (Prolia)
- Infliximab (Inflixtra)
- Leuprolide (Lupron)
- Octreotide (Sandostatin LAR)
- Reslizumab (Cinqair)
- Tocilizumab (Actemra)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)

The following medications may be administered in ICS but require at least 48 hour notification of treatment date to ensure obtainability of the product:

- Belatacept (Nulojix)
- Bezlotoxumab (Zinplava)
- Cidofovir
- Tigecycline (Tygacil)
- Fulvestrant (Faslodex)

INITIAL EFFECTIVE DATE: 04/2019

DATES REVISIONS EFFECTIVE: 09/2020, 02/2024

DATES REVIEWED (no changes):